Search Results - "Cesas, Alvydas"
Search alternatives:
- "Cesas, Alvydas" »
-
1
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)
Published in Clinical colorectal cancer (01-06-2017)“…In a phase III, double-blind trial, 845 patients with advanced colorectal cancer receiving bevacizumab plus first-line chemotherapy (FOLFOX [leucovorin),…”
Get full text
Journal Article -
2
Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer: a consensus of Lithuanian medical oncologists, radiation oncologists, endocrinologists, and family medicine physicians
Published in Medicina (Kaunas, Lithuania) (2014)“…The aim of this article is to inform about cancer treatment-induced bone loss, to identify patients at risk and those that can benefit from bone targeted…”
Get full text
Journal Article Conference Proceeding -
3
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel
Published in Wiener Klinische Wochenschrift (01-06-2010)“…Summary In breast cancer, early detection as well as new developments in therapeutic options has resulted in less patients presenting with metastatic disease…”
Get full text
Journal Article -
4
Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions
Published in Cancers (18-03-2024)“…Cutaneous melanoma, an aggressive malignancy, has undergone significant transformation in clinical management with the introduction of immune checkpoint…”
Get full text
Journal Article -
5
Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective–prospective cohort multicentre study
Published in Journal of cancer research and clinical oncology (01-08-2023)“…Purpose The purpose of our study was to determine whether data on the clinical effectiveness of second-line therapy collected in a real-world setting provide…”
Get full text
Journal Article -
6
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Published in Melanoma research (01-06-2020)“…In clinical trials, dabrafenib plus trametinib improved overall survival (OS) compared with single-agent BRAF inhibitors (BRAFi) in patients with BRAF…”
Get full text
Journal Article -
7
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial
Published in JAMA oncology (01-04-2022)“…DCVAC/PCa is an active cellular immunotherapy designed to initiate an immune response against prostate cancer. To evaluate the efficacy and safety of DCVAC/PCa…”
Get more information
Journal Article -
8
European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment
Published in European journal of cancer (1990) (01-10-2020)“…Smoking cessation after a cancer diagnosis is associated with improved overall survival. Few studies have reported oncologists' cessation practice patterns,…”
Get full text
Journal Article -
9
Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer
Published in Medicina (Kaunas, Lithuania) (2014)“…The aim of this article is to inform about cancer treatment-induced bone loss, to identify patients at risk and those that can benefit from bone targeted…”
Get full text
Journal Article -
10
P-675 Anemia in lung cancer patients and correction with EPREX (erithropoethinum alpha)
Published in Lung cancer (Amsterdam, Netherlands) (01-08-2003)Get full text
Journal Article -
11
RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis
Published in Journal of clinical oncology (20-01-2015)“…Abstract only 11 Background: RAM is a human IgG 1 monoclonal antibody VEGF-R2 antagonist. The RAINBOW trial demonstrated that RAM added to PTX significantly…”
Get full text
Journal Article -
12
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC)
Published in Journal of clinical oncology (20-05-2013)“…Abstract only 3575 Background: The literature reports that adding biologics to chemotherapy (ctx) may increase the incidence of clinically significant…”
Get full text
Journal Article -
13
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC)
Published in Journal of clinical oncology (01-02-2013)“…Abstract only LBA445 Background: The literature reports that adding biologics to chemotherapy (ctx) may increase the incidence of clinically significant…”
Get full text
Journal Article -
14
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the PAVES Study
Published in Clinical colorectal cancer (2016)“…Abstract Background Pegfilgrastim’s role in reducing febrile neutropenia (FN) risk in patients with colorectal cancer (CRC) receiving chemotherapy plus…”
Get full text
Journal Article -
15
Combined treatment of esophageal cancer: a review
Published in Medicina (Kaunas, Lithuania) (2004)“…While still relatively uncommon in many countries, esophageal cancer is fatal in the vast majority of cases. In the USA, estimated 13,100 of new cases were…”
Get more information
Journal Article -
16
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Published in The Lancet (British edition) (04-05-2019)“…First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a…”
Get full text
Journal Article